(Q30578360)

English

A comparison of the dissolution and bioavailability characteristics of three spironolactone tablet formulations, including preliminary data on two spironolactone metabolites

scientific article published on January 1, 1976

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

A comparison of the dissolution and bioavailability characteristics of three spironolactone tablet formulations, including preliminary data on two spironolactone metabolites (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

author name string

M. J. Tidd

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1037443

16 August 2022

W. T. Collins

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1037443

16 August 2022

J. Chamberlain

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1037443

16 August 2022

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1037443

16 August 2022

publication date

1 January 1976

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

Journal of International Medical Research

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

86-95

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess, and low plasma renin.

1 reference

https://api.crossref.org/works/10.1177%2F030006057600400202

21 January 2018

Comparison of spironolactone tablet dosage forms in healthy humans.

1 reference

https://api.crossref.org/works/10.1177%2F030006057600400202

21 January 2018

Resistant ascites treated by combined diuretic therapy (spironolactone, mannitol, and chlorothiazide)

1 reference

https://api.crossref.org/works/10.1177%2F030006057600400202

21 January 2018

Identifiers

10.1177/030006057600400202

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30578360&oldid=1888901911"